{"status": "Ok", "redirect_url": "https://www.prnewswire.com//news-releases/neurosense-achieves-primary-endpoint-in-phase-2b-als-study-with-statistically-significant-reduction-of-tdp-43-the-defining-pathological-hallmark-of-als-302813175.html", "message": "News view counter 820618 successfully enlarged"}